New York, USA - October 20, 2022 - Neutralizing antibodies (NAbs) against SARS-CoV-2 have been demonstrated as one of the most efficient therapeutics by means of interfering with virion binding to receptors, blocking virus uptake into host cells, and preventing uncoating of viral genomes in the endosome, etc. Meanwhile, recombinant sdAbs constitute attractive alternatives for the production of neutralizing therapeutic agents against SARS-CoV-2 due to their small size and enhanced hydrophilicity. Therefore, Creative Biolabs is hosting a fireside chat, entitled "A potent SARS-CoV-2 neutralizing single-domain antibody (sdAb) shows therapeutic efficacy in the Syrian golden hamster model of COVID-19" that takes place on Tuesday, October 25 at 11 AM EDT / 4 PM BST, to elucidate the most advanced therapeutic potential of sdAbs.
This live webinar will explore the significance of SARS-CoV-2 neutralizing sdAbs in COVID-19 treatment, in which Dr. Naismith from the University of Oxford is featured to share his insights and showcase the therapeutic efficacy of a novel potent SARS-CoV-2 neutralizing sdAbs developed by his team utilizing the Syrian golden hamster model.
"It's been thrilling to have Dr. Naismith in our virtual event and share his experience in developing this novel therapeutic sdAb against COVID-19. As you know, Creative Biolabs has long been dedicated to single-domain antibody discovery and helping researchers achieve their goals of applying sdAbs in therapeutic, diagnostic, and other fields," said the host of this webinar. "I look forward to talking to Dr. Naismith and highlighting some of the most impactful strategies researchers can draw on within their projects."
In this 45-minute webinar, attendees will learn how Dr. Naismith and his team developed this novel SARS-CoV-2 neutralizing sdAbs and how they discovered a promising therapeutic candidate in a hamster model of COVID-19. More details and the latest achievements of their research will also be discussed, including:
* SdAbs that bind to the SARS-CoV-2 have been identified from both naive library and lama challenge.
* SdAbs are proven to target two broad epitopes, highlighting the role of E484 in first-generation agents.
* Two potent formulations are possible to be made in the hamster therapeutic model.
Additionally, registrants will have a 15-minute opportunity to ask burning questions and learn tips and tricks to capitalize on in sdAb research, as well as common pitfalls to avoid.
Register here to attend this free virtual event online.
About
Creative Biolabs is the leading CRO trusted by global biotech companies and academic organizations. Creative Biolabs' comprehensive platforms and extensive experience in antibody development underpin its core solution - novel single-domain antibody discovery. In order to enhance sdAb research and applications in different scenarios, the company has streamlined a wide range of services for sdAb development, characterization, improvement, production, and manufacturing.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/sdab
